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ABSTRACT
Extended-spectrum b-lactamases (ESBLs) represent a major threat among resistant bacterial isolates.
The ﬁrst types described were derivatives of the TEM-1, TEM-2 and SHV-1 enzymes during the 1980s in
Europe, mainly in Klebsiella pneumoniae associated with nosocomial outbreaks. Nowadays, they are
mostly found among Escherichia coli isolates in community-acquired infections, with an increasing
occurrence of CTX-M enzymes. The prevalence of ESBLs in Europe is higher than in the USA but lower
than in Asia and South America. However, important differences among European countries have been
observed. Spread of mobile genetic elements, mainly epidemic plasmids, and the dispersion of speciﬁc
clones have been responsible for the increase in ESBL-producing isolates, such as those with TEM-4,
TEM-24, TEM-52, SHV-12, CTX-M-9, CTX-M-14, CTX-M-3, CTX-M-15 and CTX-M-32 enzymes.
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INTRODUCTION
Extended-spectrum b-lactamases (ESBLs) repre-
sent a major threat among multidrug-resistant
bacterial isolates. They have been increasingly
described worldwide since their description in
the early 1980s and have risen to prominence
among Enterobacteriaceae isolates in nearly all
European countries, now not only in the nosoco-
mial but also in the community setting [1–3]. This
review focuses on current European ESBL epide-
miology. The population structure of ESBL-pro-
ducing isolates and the nature of mobile genetic
elements carrying blaESBL genes are analysed.
ESBLS HAVE MAINLY EMERGED IN
EUROPE
ESBLs are enzymes inhibited by clavulanic acid
and other inhibitors of class A b-lactamases, such
as sulbactam and tazobactam. They confer resis-
tance or decrease susceptibility to narrow- and
expanded-spectrum cephalosporins, but do not
affect cephamycin and carbapenem compounds
[4]. Different groups of ESBLs, classiﬁed accord-
ing to their amino-acid sequences, have been
described, and most of them were ﬁrst recognised
in Europe (Table 1) [5–21]. The ﬁrst ESBL was
detected in Germany in 1983, among different
enterobacterial isolates recovered from inpatients
at intensive care units (ICUs). It was recognised
by the producer strains abnormal resistance to
cefotaxime and ceftazidime, which was transfer-
able by conjugation to Escherichia coli [5]. These
isolates had a variant of the classic SHV-1 with a
single amino-acid change, and this was named
SHV-2. Very soon afterwards in France, in 1984,
Klebsiella pneumoniae isolates with an identical
phenotype were detected in different hospitals
and, in this case, a variant of the broad-spectrum
TEM-2 b-lactamase was identiﬁed. This enzyme
was ﬁrst named CTX-1 and later TEM-3. It has
two amino-acid substitutions when compared
with the parental enzyme. As with SHV-2, the
corresponding phenotype associated with this
enzyme was also transferable by conjugation [6].
Different epidemics have since been reported, and
new ESBL variants of both groups have been
identiﬁed in Europe and other geographical areas
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[22]. Both TEM and SHV ESBL enzymes are now
distributed worldwide, with more than 160 and
100 variants, respectively, recognised (http://
www.lahey.org/studies/webt.htm). They have
been associated with Enterobacteriaceae species,
mostly K. pneumoniae and Enterobacter spp. iso-
lates recovered from ICU patients, and more
recently with Pseudomonas aeruginosa and Acinet-
obacter baumannii [23].
In 1989, almost simultaneously in Germany and
Argentina and then in France and Italy, a new
ESBL family was recognised. It was named
CTX-M, because most of the enzymes within this
family confer resistance predominantly to cefo-
taxime rather than ceftazidime [7,9]. The CTX-M
ESBLs have since been detected in many species
of Enterobacteriaceae. Previously, in 1986, a
b-lactamase (FEC-1) with a similar phenotype
was identiﬁed in Japan in an E. coli isolate
recovered from a research laboratory animal [8].
Now, at least 65 CTX-M variants have been
recorded, and are clustered in ﬁve different
groups according to their amino-acid sequences,
typiﬁed by CTX-M-1, CTX-M-2, CTX-M-8, CTX-
M-9 and CTX-M-25 (http://www.lahey.org/
studies/webt.htm). Some representatives of these
groups were ﬁrst recognised in Europe (Table 1).
A close relationship between CTX-M enzymes
and different chromosomal b-lactamases from
Kluyvera spp. has been recognised, and mobilisa-
tion of these chromosomal genes to plasmids
might involve speciﬁc sequences such as insertion
sequences (ISs) (ISCR1 and ISEcp1) or phages
[2,24–26].
In 1991 in Ankara (Turkey), and later in France,
oxacillinases conferring a phenotype similar to
that of ESBLs, but with little inhibition by clavul-
anate, were found [13]. They were recognised as
mutants of broad-extended-spectrum OXA-type
b-lactamases (most of them OXA-10). These vari-
Table 1. Different extended-spectrum b-lactamase (ESBL) families and groups, and type of ESBL and country of
emergence
ESBL Progenitor b-lactamase Country of emergence
Bacterial species in
which these enzymes
were ﬁrst detected Reference
High prevalence
SHV SHV-1 ⁄LEN (>90%)a Germany (1983)b Enterobacteriaceae [5]
TEM TEM-1, -2 (>90%)a France (1985)b Enterobacteriaceae [6]
CTX-M-1 group KLUC Kluyvera cryocrencens
(85%)a
Germany (1989)c Escherichia coli [7]
CTX-M-2 group KLUA Kluyvera ascorbata
(80–100%)a
Japan (1986)c ⁄Argentina
(1989)c
E. coli, Salmonella spp. [8,9]
CTX-M-8 group KLUG Kluyvera georgiana (95%)a Brazil (1996–1997)c Citrobacter amalonaticus,
Enterobacter spp.
[10]
CTX-M-9 group KLUG K. georgiana (80%)a Spain (1994)c E. coli [11]
CTX-M-25 group ND Canada (2000)c E. coli [12]
OXA OXA-10 (PSE-2) (>90%)a Turkey (1991)c Pseudomonas aeruginosa [13]
PER France (1991)c P. aeruginosa [14]
VEB PER (39%)a France (Vietnamd)
(1996)c
E. coli [15]
Low prevalence
SFO AmpA Serratia fonticola (96%)a Japan (1988)c Enterobacter cloacae [16]
TLA CME-1 (50%)a Chryseobacterium
meningosepticum
Mexico (1991)c E. coli [17]
BES YENT (51%)a Yersinia enterocolitica Brazil (1996)c Serratia marcescens [18]
GES-1 YENT (36%)a Y. enterocolitica France (French Guyanad)
(1998)c
Klebsiella pneumoniae [19]
IBC YENT (40%)a Y. enterocolitica Greece (1999)c E. cloacae [20]
BEL GES-1 (50%)a Belgium (2004)c P. aeruginosa [21]
ND, not determined.
aAmino-acid sequence homology (%).
bDate of publication.
cIsolation date.
dOrigin of the patient in whom the corresponding enzyme was ﬁrst detected.
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ants have since been found worldwide, includ-
ing in Europe, and are mainly associated with
P. aeruginosa and, to a lesser extent, with A. bau-
mannii or Enterobacteriaceae [27,28]. Other, less-
prevalent, ESBL groups include PER enzymes,
mainly found in P. aeruginosa and Acinetobacter
spp., and VEB and GES in P. aeruginosa and
Enterobacteriaceae (Table 1) [1,14,15,19,28]. These
are often transferable and are inhibited by clavul-
anate. Even rarer types include SFO, TLA, BEL,
BES and IBC enzymes [1,16–18,20,21,29].
CHANGING EPIDEMIOLOGY OF
ESBLS
Until the end of the 1990s: (i) most of the ESBLs
detected were SHV and TEM types; (ii) isolates
expressing these enzymes were almost associated
with nosocomial outbreaks, mainly in ICUs, and it
was very unusual for them to be associated with
community-acquired infections; and (iii) the prev-
alence of ESBL producers was higher among
K. pneumoniae than among E. coli isolates [30].
Identiﬁed risk-factors included admittance to
ICUs, recent surgical procedures, use of catheters,
bladder catheterisation, long-term hospitalisation
and previous use of cephalosporins and ⁄ or am-
inoglycosides [1,31].
This situation has changed dramatically in the
last few years, and most ESBL-producing iso-
lates are now E. coli expressing CTX-M b-lacta-
mases. The majority of these isolates are now
recovered from community patients, most of
them with urinary tract infections, and the
number of isolates expressing ESBLs has in-
creased in non-ICU areas at the hospital [32–34].
In addition, new risk-factors, including prior
ﬂuoroquinolone use, have also been identiﬁed
[33]. Unlike that of TEM or SHV ESBLs, the
population structure of CTX-M-producing iso-
lates is complex and is associated with the
spread of speciﬁc plasmids and ⁄ or other mobile
genetic elements rather than clonal epidemics
[35–38]. Nevertheless, recent studies, most of
them European, have identiﬁed epidemics in the
community due to E. coli isolates with plasmids
harbouring blaCTX-M genes [2]. In addition, and
resembling the scenario described with methi-
cillin-resistant Staphylococcus aureus isolates, an
increase in ESBL-producing isolates has been
detected in nursing homes and healthcare-asso-
ciated facilities in the community, with the
potential inﬂux of ESBLs from the community
to the hospital [34].
COMPLEX EPIDEMIOLOGY OF ESBLS
IN EUROPE
Increasing prevalence, including faecal carriers
of isolates producing ESBLs
Different surveillance studies performed inEurope
and other geographical areas have shown an
increased prevalence and dispersion of ESBL-
producing isolates. The latest available EARSS
data reﬂect the increase in invasive E. coli isolates,
recovered from blood cultures, that are resistant to
extended-spectrum cephalosporins. The propor-
tion of such isolates that may express ESBLs are as
high as 28% in Bulgaria, 16% in Cyprus and
Romania and 12% in Portugal [39] (http://
www.rivm.nl/earss/result/). Similarly, the MYS-
TIC surveillance programme (Meropenem Yearly
Susceptibility Test InformationCollection) showed
an increase in ESBL-producing E. coli isolates from
1997 (2.1%) to 2004 (10.8%). Corresponding ﬁg-
ures for other Enterobacteriaceae indicated an
increase in the prevalence among K. pneumoniae
isolates (from 9.0% to 13.6%) and, to a lesser
extent, among Enterobacter spp., Citrobacter spp.
and Proteus mirabilis isolates (<4% of isolates in
2004) [40]. This situation is unlike that observed in
the USA, where ESBL-producing isolates are less
prevalent than in Europe, and where MYSTIC
indicated a decrease in ESBL frequency in E. coli
(from 5.1% to 1.4%) and K. pneumoniae isolates
(from 7.2% to 4.4%) during the same period [40].
Previous publications of the MYSTIC studies
showed that the distribution of ESBL-producing
Enterobacteriaceae isolates in Europe varied
among countries, the highest rates being in Russia
(nearly 50%) and Poland (nearly 40%) in 2000 [41].
Similar ﬁndings were also made in the SENTRY
and SMART surveillance programmes. In the ﬁrst
one between 1997 and 1999, an increase in the
frequency of ESBL-producing isolates was
observed for K. pneumoniae, P. mirabilis and E. coli
isolates, with a higher prevalence in Europe than
in the USA but lower than in South America and
Asia [30]. Recent data from this surveillance
programme indicate that, in Europe, 1.3% of
E. coli, 18.4% of K. pneumoniae, 2.6% of Klebsiella
oxytoca and 5.3% of P. mirabilis isolates express an
ESBL phenotype [42]. These frequencies are much
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lower than those observed in Asia [43]. The 2004
SMART study showed that at least 10% of E. coli
isolates recovered worldwide from intra-abdom-
inal infections were ESBL producers, as were 17%
of Klebsiella spp. and 22% of Enterobacter spp.
isolates [44,45]. This increase can be related to the
increase in faecal carriers over time and contam-
ination of the abdominal cavity or organs follow-
ing rupture, trauma or surgery. The issue of
carriage has been addressed in different European
countries for hospitalised and community pa-
tients, including those from healthcare facilities
and nursing homes. Data from Spain showed the
dramatic increase in faecal carriers from 1991 to
2003 among hospitalised (<1% and 12%, respec-
tively) and community (<1% and 5%, respectively)
patients; the prevalence reached nearly 4% in
healthy volunteers in 2003 [46]. This situation was
corroborated in other studies, with ﬁgures ranging
from 2% in 2001 to 7% in 2004 in non-hospitalised
patients [47,48]. This percentage is even higher in
Israel, where at least 11% of patients requiring
hospitalisation were faecal carriers of ESBL-pro-
ducing isolates [34]. These rates could be even
higher in nursing homes and among haematology
patients [49,50].
National surveillance studies have also shown
the increase in prevalence of ESBL-producing
isolates over time. France, Italy, Spain, Belgium
and Poland all exemplify these trends [3,51–54].
In Spain, a 40-centre study performed during a
4-month period in 2000 showed ESBL prevalence
rates in K. pneumoniae and E. coli of 2.7% and
0.5%, respectively. Most of the K. pneumoniae
isolates (93%) were found in hospitalised pat-
ients, whereas 51% of E. coli isolates were asso-
ciated with community-acquired infections [54].
Preliminary data from a new surveillance study in
Spain in 2006 indicated further increases in
prevalence, to 8% of K. pneumoniae and 6% of
E. coli isolates (A. Pascual, personal communica-
tion). In Italy, the prevalence of ESBL producers
in 2003 was 7.4% among isolates from inpatients
and 3.5% among isolates from outpatients.
Among hospitalised patients, the most prevalent
ESBL-positive species was E. coli (K. pneumoniae
in 1999), and among outpatients, the most pre-
valent ESBL-positive species was P. mirabilis.
Most of the producer isolates were obtained from
urinary tract infections [52]. Researchers from
other countries, such as the UK, have raised the
alarm about the sudden increase in ESBL-pro-
ducing isolates in the community setting [55]. The
prevalence of ESBL-producing Enterobacteriaceae
is lower in the UK than in other several European
countries, but producers seem to have spread
mainly in the community [56,57]. Generally, it is
also noticeable that countries in the north and
north-west of Europe, traditionally with low rates
of antimicrobial resistance, such as Germany,
Norway and Sweden, have found signiﬁcant
prevalence rates of ESBLs[58–60].
Increased diversity of ESBLs and different
distribution of ESBLs in Europe
Recent European studies have conﬁrmed the
persistence of TEM and SHV ESBLs and the
increase in CTX-M producers among Enterobac-
teriaceae. The identiﬁcation of other ESBLs
remains rare, and when detected they have been
mostly found in P. aeruginosa and Acinetobacter
[1,3,27]. Pooling different European studies, it
seems that certain isolates expressing speciﬁc
enzymes are better adapted to speciﬁc environ-
ments and geographical areas. Moreover, in the
last few years, new ESBL variants from different
families, including CTX-M, have emerged. In
addition, it has been suggested that co-resistance
might have played a relevant role in the current
endemic situation, allowing the maintenance of
ESBL-producing organisms. Other ESBLs are
linked to speciﬁc clones and ⁄ or plasmid incom-
patibility groups, and have been shown to be
widespread in some European countries [2].
TEM family.
Continuous monitoring by a Polish reference
laboratory shows the evolution of TEM ESBLs in
this country [61]. The emergence of new TEM
ESBL variants has been shown in France, Italy,
Spain, Belgium and Portugal, as has the spread of
speciﬁc epidemic clones such as those of Enterob-
acter aerogenes with TEM-24 [62–68]. TEM-3 and
TEM-4 also seem to be widespread, and to be
associated with different clones of K. pneumoniae
in ICUs [69,70]. TEM-52 is also widespread in
Europe, and is associated with Salmonella isolates
and, more recently, with E. coli from urinary tract
infections [68,71–73].
SHV family.
SHV-12 is one of the most prevalent enzymes
within the SHV family. It has been reported all
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over the world in K. pneumoniae and, more
recently, in E. coli from community patients
[46,54,74]. The presence of the corresponding
blaSHV-12 gene has been associated with genetic
elements conferring resistance to ﬂuoroquinol-
ones, (qnr) which may have contributed to its
dispersion [75,76]. SHV-12 has also been found in
isolates expressing other ESBLs such as TEM, GES
and CTX-M types [77–80]. The presence of more
than one ESBL in a single isolate is increasingly
being detected, and the reasons for this situation
need further investigation.
CTX-M family.
Within the CTX-M family, the CTX-M-9 cluster
has been shown to be highly represented in Spain.
In particular, CTX-M-14 is frequently detected in
E. coli isolates recovered from non-hospitalised
patients [33,81]. These enzymes have also been
reported in Portugal, France and the UK, but are
infrequent in other European countries (Fig. 1).
Within the CTX-M-1 cluster, CTX-M-1 and
CTX-M-32 were originally found to be prevalent
in the Mediterranean area, but nowadays they are
prevalent in nearly all European countries. CTX-
M-15 has risen to prominence all over Europe,
whereas CTX-M-3 is mainly described in eastern
European countries [3]. CTX-M-15 was initially
detected in an isolate recovered in India in 2001
[82]. It is distinguished from CTX-M-3 by a point
mutation that increases hydrolytic activity against
ceftazidime.
CTX-M-15-producing isolates have been
increasingly recognised in community isolates,
particularly in healthcare-associated patients, and
more recently in the nosocomial setting
[35,36,57,83,84]. The successful dispersion of
CTX-M-15 has been associated with speciﬁc
clones, particularly in the UK, and the transfer
of speciﬁc epidemic plasmids harbouring the
blaCTXM-15 gene. These epidemic plasmids have
been identiﬁed in Europe (Spain, France, Portu-
gal, Austria, UK), Africa (Tunisia and Central
Africa Republic) and North America (Canada)
[35,38,85,86]. It is of note that some of the
epidemic E. coli clones expressing CTX-M-15 in
Endemicity Sporadic reports 
CTX-M-1,10,15,32 
CTX-M-9,-14 
CTX-M-1,3,10,15 
CTX-M-2, 5 
CTX-M-9, -14, 18, 19, 20, 21 
CTX-M-4,6 
CTX-M-, 3, 15 
CTX-M-1,3,15,33 
CTX-M-15 
CTX-M-2 
CTX-M-1,15,32 
CTX-M-1,3,15 
CTX-M-40 
CTX-M-1,15,32 
CTX-M-2 
CTX-M-3,15 
CTX-M-15 
CTX-M-9,14,17,18 
CTX-M-3,15 
CTX-M-3,15 
CTX-M-2,4,5 
CTX-M-14 
CTX-M-9 
CTX-M-9, 16 
CTX-M-2 
CTX-M-1 
CTX-M-9 
CTX-M-3,15 
CTX-M-2 
CTX-M-8 
CTX-M clusters 
CTX-M-25 
CTX-M-26 
Fig. 1. Distribution of CTX-M enzymes in Europe.
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the UK may also express plasmid AmpC en-
zymes, which further limits therapeutic options
and may become a new threat in the future [85].
Unlike in South America and Asia, the CTX-M-
2 cluster is unevenly represented in Europe, with
different variants appearing in different areas,
particularly in Russia, Israel and eastern countries
[86,87]. In Spain, it has been scarcely found,
despite the relationship of this country with South
America, where this cluster is highly prevalent
[1,88]. Moreover, E. coli strains with CTX-M-2
were recently isolated from chicken meat samples
imported to the UK from The Netherlands and
Brazil. Recently, CTX-M-2 has been found associ-
ated with nosocomial isolates of A. baumannii in
Japan [89].
In Europe, the CTX-M-8 cluster is only repre-
sented in the UK, by the CTX-M-40 variant [90].
CTX-M-26 from the CTX-M-25 cluster has also
been detected in the UK [12].
FEATURES FUELLING THE INCREASE
OF ESBL-PRODUCING ISOLATES
Different features affecting the increase of ESBLs
have been discussed previously, particularly for
CTX-M enzymes [2]. Previous use of expanded-
spectrum cephalosporins, aminoglycosides and,
more recently, ﬂuoroquinolones has been recog-
nised as a risk-factor for infections with ESBL-
producing organisms. The presence of genetic
platforms containing multiple antibiotic resis-
tance genes ensures co-selection of ESBL pro-
cesses. For example, blaCTX-M-2 and blaCTX-M-9
genes can be linked to class 1 integrons bearing
ISCR1, often linked with mercury resistance
transposons such as Tn21 [37,88,91]. These integ-
rons may carry different resistance cassettes, such
as those conferring resistance to aminoglycosides,
trimethoprim and sulphonamide compounds.
Moreover, the association of blaESBL genes with
genetic determinants encoding emerging resis-
tance mechanisms has also been described,
mostly with CTX-M enzymes. These include 16S
RNA methylase (armA and rtmB genes linked to
CTX-M-3), different Qnr proteins (QnrA linked
with CTX-M-1, -15 and -9; QnrB with CTX-M-15;
and QnrS with CTX-M-1 and -9) and a ﬂuro-
quinolone acetyltranferase [aac(6¢)-Ib-cr with
CTX-M-15] [76,92–99].
Although transposons and ISs are important
elements in the mobilisation and spread of blaESBL
genes, plasmids also play an important role in the
dissemination of these genes. Early in the 1990s,
blaSHV and blaTEM were associated with a few
speciﬁc incompatibility groups of plasmids
(IncM, IncA ⁄C, IncFI, and IncHI2) with variable
size (40–300 kb) and frequency of transfer (10)2 to
>10)9) that had been present for several years in
resistant bacteria [100]. A similar situation seems
to have occurred with different blaCTX-M genes.
International dissemination of blaCTX-M-15 seems
to be associated with IncFII plasmids [101,103],
whereas blaCTX-M-32 is associated with IncN plas-
mids [38] and blaCTX-M-9 with IncHI2 [37]. Some of
these Inc groups are broad-host-range plasmids
that might allow future dissemination in non-
Enterobacteriaceae isolates [2]. Finally, in E. coli,
speciﬁc association of different phylogenetic
groups has been suggested: B2 phylogenetic
group mainly with CTX-M-15, A with CTX-M-14
and CTX-M-9, or both A and D with SHV-12
[2,37]. Some of these isolates also harbour
virulence determinants, such as those carrying
blaCTX-M-15 [101–103]. However, most of these
studies have been performed with ESBL-produc-
ing isolates from single geographical sources, and
wider investigations may be useful to identify
patterns of association, not only to trace the
emergence and evolution of ESBLs in different
geographical areas, but also to develop future
measures to curtail their spread.
CONCLUSION
ESBLs were ﬁrst described in Europe as variants
of TEM and SHV broad-spectrum b-lactamases.
CTX-M enzymes, now increasingly dominant,
were also ﬁrst detected in this continent. During
the 1980s and 1990s, there were important noso-
comial outbreaks associated with ESBL-produc-
ing K. pneumoniae isolates, but E. coli producer
isolates have now risen to prominence, mainly
associated with community-acquired infections.
The prevalence of ESBLs in Europe is higher than
in the USA but lower than in Asia and South
America, although important differences among
European countries have been observed. The
spread of mobile genetic elements, mainly conju-
gative plasmids belonging to classic incompati-
bility groups, and the dispersion of speciﬁc clones
have been responsible for the increase in ESBL-
producing isolates and for the spread of TEM-4,
TEM-24, TEM-52, SHV-12, CTX-M-9, CTX-M-14,
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CTX-M-3, CTX-M-15 and CTX-M-32 in particular.
Co-selection with other resistances, including
quinolone resistance, may also have contributed
to the current epidemiological ESBL scenario.
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